Figure 1.
Neutralization and antibody binding of postvaccination serum against SARS-CoV-2 WA1/2020 strain and variants of concern. Neutralization assays were performed with the use of pseudoviruses expressing the SARS-CoV-2 spike proteins of the WA1/2020 vaccine strain or the Alpha, Beta, Gamma, Delta, and Omicron variants. (A) Serum samples following 2 doses of SARS-CoV-2 mRNA vaccination were obtained from 38 patients with AML/MDS (P; in red) or 16 healthy controls (C; in blue). (B) Vaccination samples from after the third vaccination were obtained from 11 patients with AML/MDS and 16 healthy controls. The heights of the bars and the numbers over the bars indicate the GMTs; the whiskers indicate 95% confidence intervals and are color-coded. The assay of each serum sample was performed in duplicate. Each data point represents an individual sample (circles) and indicates the 50% neutralization titer obtained with each sample against the corresponding pseudovirus. The horizontal dashed line indicates the limit of detection for the neutralization assay (PsVNA50 of 20). The raw data and information regarding the serum samples from vaccinated participant (sex, age, vaccine type, and samples collected postvaccination and 50% neutralization titers against various SARS-CoV-2 strains) are summarized in supplemental Table 2. Differences between SARS-CoV-2 strains were analyzed by lme4 and emmeans packages in R using Tukey pairwise multiple comparison test and the P values are shown. (C,D) SARS-CoV-2 RBD-binding IgG to vaccine-homologous WA1/2020 and Omicron variant in serum samples following 2 doses of SARS-CoV-2 mRNA vaccination (C) from 38 patients with AML/MDS (P; in red) and 16 healthy controls (C; in blue) or following 3 doses of vaccination (D) from 11 patients with AML/MDS (P; in red) and 16 healthy controls (C; in blue). Each serum sample was evaluated in IgG-ELISA in duplicate to determine the RBD-binding IgG end-point titer against RBD of either WA1/2020 or the Omicron variant. The height of bars and numbers over the bars indicate the IgG GMTs, and the whiskers indicate 95% confidence intervals. The horizontal dashed line indicates the limit of detection for IgG ELISA (1:100). Statistical differences between patients and controls were analyzed by lme4 and emmeans packages in R using Tukey pairwise multiple comparison test and the P values are shown. ELISA, enzyme-linked immunosorbent assay.

Neutralization and antibody binding of postvaccination serum against SARS-CoV-2 WA1/2020 strain and variants of concern. Neutralization assays were performed with the use of pseudoviruses expressing the SARS-CoV-2 spike proteins of the WA1/2020 vaccine strain or the Alpha, Beta, Gamma, Delta, and Omicron variants. (A) Serum samples following 2 doses of SARS-CoV-2 mRNA vaccination were obtained from 38 patients with AML/MDS (P; in red) or 16 healthy controls (C; in blue). (B) Vaccination samples from after the third vaccination were obtained from 11 patients with AML/MDS and 16 healthy controls. The heights of the bars and the numbers over the bars indicate the GMTs; the whiskers indicate 95% confidence intervals and are color-coded. The assay of each serum sample was performed in duplicate. Each data point represents an individual sample (circles) and indicates the 50% neutralization titer obtained with each sample against the corresponding pseudovirus. The horizontal dashed line indicates the limit of detection for the neutralization assay (PsVNA50 of 20). The raw data and information regarding the serum samples from vaccinated participant (sex, age, vaccine type, and samples collected postvaccination and 50% neutralization titers against various SARS-CoV-2 strains) are summarized in supplemental Table 2. Differences between SARS-CoV-2 strains were analyzed by lme4 and emmeans packages in R using Tukey pairwise multiple comparison test and the P values are shown. (C,D) SARS-CoV-2 RBD-binding IgG to vaccine-homologous WA1/2020 and Omicron variant in serum samples following 2 doses of SARS-CoV-2 mRNA vaccination (C) from 38 patients with AML/MDS (P; in red) and 16 healthy controls (C; in blue) or following 3 doses of vaccination (D) from 11 patients with AML/MDS (P; in red) and 16 healthy controls (C; in blue). Each serum sample was evaluated in IgG-ELISA in duplicate to determine the RBD-binding IgG end-point titer against RBD of either WA1/2020 or the Omicron variant. The height of bars and numbers over the bars indicate the IgG GMTs, and the whiskers indicate 95% confidence intervals. The horizontal dashed line indicates the limit of detection for IgG ELISA (1:100). Statistical differences between patients and controls were analyzed by lme4 and emmeans packages in R using Tukey pairwise multiple comparison test and the P values are shown. ELISA, enzyme-linked immunosorbent assay.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal